Dermatitis atopic
Not recruitingStudy on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis Using Topical Corticosteroids
Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis Using Topical Corticosteroids
- Disease:Dermatitis atopic
- Substances:AmlitelimabPimecrolimus+1
Germany- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Amlitelimab
- Sponsor:Sanofi-Aventis Recherche & Developpement













